Optiscan was recently featured in both The Australian and Stockhead regarding its groundbreaking work in cancer surgery through confocal laser endomicroscopy (CLE). This innovative technology enables real-time imaging of tissue, effectively eliminating the need for painful biopsies and significantly enhancing surgical precision.

CEO Dr. Camile Farah highlighted a critical issue in breast cancer treatment: an astonishing 25% to 30% of cases require second surgeries because the initial surgery fails to excise all of the tumor. Dr. Farah remarked, “Imagine if your wife or daughter is told they have breast cancer. They have to go through the physical and mental trauma all over again. We want to ensure it is done right the first time.”

Optiscan is committed to addressing this challenge with its advanced CLE technology, which utilizes a single optical fiber in a probe to project laser light onto live tissue treated with fluorescent dye. This process produces real-time digital microscopic images with a magnification 1000 times greater than traditional imaging methods like CT or MRI.

The company is preparing to launch its third product, targeting pathology labs, by the end of the year. As Optiscan navigates the complexities of US medical device regulations and commercialization, Dr. Farah emphasizes that the core mission remains focused on improving outcomes for both patients and clinicians.

The Australian - Access the full article here.

Stockhead - Access the full article here.